The significance of insufficiency fractures in rheumatic musculoskeletal diseases

Abstract

Osteoporosis is a systemic skeletal disease characterized by low bone mineral density (BMD) and poor bone quality, leading to reduced bone strength and increased risk of fracture. In rheumatic and musculoskeletal diseases (RMD), including rheumatoid arthritis (RA) and spondyloarthritides (SpA), such as axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), generalized bone loss associated with traumatic and non-traumatic fractures, such as insufficiency fractures (IF), is known to occur with the RANK-RANKL-osteoprotegerin axis and the Wnt-β-catenin signalling pathway playing a pathogenetic role. RA has been included in the Fracture Risk Assessment Tool (FRAX) system to be able to more precisely calculate the 10-year fracture risk associated with the disease. Various definitions for IF have been proposed; a recent paper by the EMA has defined fragility fractures as fractures occurring with low trauma at the hip, spine, pelvis, distal femur, proximal tibia, humerus, forearm, and multiple ribs. However, IF of the feet are currently not considered osteoporotic fractures. So-called stress fractures, which are known to often occur in athletes, have a similar MRI appearance. However, these are rather due to repetitive strain than to minor trauma. Also, based on recent data, this manuscript concentrates on the significance of fragility fractures in RMD.

Keywords

osteoporosis / fragility fractures / bone mineral density / stress fractures

References

[1] Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006; 194: S3-11.

[2] Khandelwal S, Lane NE. Osteoporosis: Review of Etiology, Mechanisms, and Approach to Management in the Aging Population. Endocrinol Metab Clin North Am. 2023; 52: 259-75.

[3] Raterman HG, Bultink IE, Lems WF. Osteoporosis in patients with rheumatoid arthritis: an update in epidemiology, pathogenesis, and fracture prevention. Expert Opin Pharmacother. 2020; 21: 1725-37.

[4] Bremander A, Petersson IF, Bergman S, Englund M. Population-Based Estimates of Common Comorbidities and Cardiovascular Disease in Ankylosing Spondylitis. Arthritis Care Res (Hoboken). 2011; 63: 550-6.

[5] Ogdie A, Harter L, Shin D, Baker J, Takeshita J, Choi HK, et al. The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study. Ann Rheum Dis. 2017; 76: 882-5.

[6] Ørnbjerg LM, Østergaard M. Assessment of structural damage progression in established rheumatoid arthritis by conventional radiography, computed tomography, and magnetic resonance imaging. Best Pract Res Clin Rheumatol. 2019; 33: 101481.

[7] van der Heijde D, Braun J, Deodhar A, Baraliakos X, Landewé R, Richards HB, et al. Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. Rheumatology (Oxford). 2019; 58: 388-400.

[8] Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007; 13: 156-63.

[9] Deal C. Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol. 2009; 5: 20-7.

[10] Soós B, Szentpétery Á, Raterman HG, Lems WF, Bhattoa HP, Szekanecz Z. Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2022; 18: 249-57.

[11] Kanis JA, Johansson H, McCloskey EV, Liu E, Schini M, Vandenput L, et al. Rheumatoid arthritis and subsequent fracture risk: an individual person meta-analysis to update FRAX. Osteoporos Int. 2025; 36: 653-71.

[12] Osteoporosis: assessing the risk of fragility fracture. London: National Institute for Health and Care Excellence (NICE); 2017.

[13] Sanders KM, Pasco JA, Ugoni AM, Nicholson GC, Seeman E, Martin TJ, et al. The Exclusion of High Trauma Fractures May Underestimate the Prevalence of Bone Fragility Fractures in the Community: The Geelong Osteoporosis Study. J Bone Miner Res. 1998; 13: 1337-42.

[14] Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A. The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds. Osteoporos Int. 2001; 12: 417-27.

[15] European Medicines Agency. Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. London: European Medicines Agency; 2006.

[16] Fredericson M, Jennings F, Beaulieu C, Matheson GO. Stress Fractures in Athletes. Top Magn Reson Imaging. 2006; 17: 309-25.

[17] Berger FH, de Jonge MC, Maas M. Stress fractures in the lower extremity. The importance of increasing awareness amongst radiologists. Eur J Radiol. 2007; 62: 16-26.

[18] Lingg GM, Soltèsz I, Kessler S, Dreher R. Insufficiency and stress fractures of the long bones occurring in patients with rheumatoid arthritis and other inflammatory diseases, with a contribution on the possibilities of computed tomography. Eur J Radiol. 1997; 26: 54-63.

[19] Boutry N, Flipo RM, Cotten A. MR Imaging Appearance of Rheumatoid Arthritis in the Foot. Semin Musculoskelet Radiol. 2005; 9: 199-209.

[20] Briot K, Geusens P, Em Bultink I, Lems WF, Roux C. Inflammatory diseases and bone fragility. Osteoporos Int. 2017; 28: 3301-14.

[21] Yurtsever A, Fagerberg SK, Rasmussen C. Insufficiency fractures of the knee, ankle, and foot in rheumatoid arthritis: A case series and case-control study. Eur J Rheumatol. 2020; 7: 124-9.

[22] van der Leeden M, Steultjens MP, Ursum J, Dahmen R, Roorda LD, Schaardenburg DV, et al. Prevalence and Course of Forefoot Impairments and Walking Disability in the First Eight Years of Rheumatoid Arthritis. Arthritis Rheum. 2008; 59: 1596-602.

[23] Wilson O, Hewlett S, Woodburn J, Pollock J, Kirwan J. Prevalence, impact and care of foot problems in people with rheumatoid arthritis: results from a United Kingdom based cross-sectional survey. J Foot Ankle Res. 2017; 10: 46.

[24] Dakkak YJ, Jansen FP, DeRuiter MC, Reijnierse M, van der Helm-van Mil AHM. Rheumatoid Arthritis and Tenosynovitis at the Metatarsophalangeal Joints: An Anatomic and MRI Study of the Forefoot Tendon Sheaths. Radiology. 2020; 295: 146-54.

[25] Taylor-Williams O, Keen H, Preen DB, Nossent J, Inderjeeth CA. First fracture in rheumatoid arthritis: analysis by fracture site, gender, age, and comorbidities. Osteoporos Int. 2025; 36: 113-21.

[26] Giraudo C, Fichera G, Ganguly S, Arumugam M, Cecchin D, Rennie WJ. Ankle and Foot: Focus on Inflammatory Disease. Semin Musculoskelet Radiol. 2023; 27: 327-36.

[27] Amor B, Dougados M, Listrat V, Menkes CJ, Dubost JJ, Roux H, et al. Evaluation of the Amor criteria for spondylarthropathies and European Spondylarthropathy Study Group (ESSG). A cross-sectional analysis of 2,228 patients. Ann Med Interne (Paris). 1991; 142: 85-9. French.

[28] Krabbe S, Renson T, Jans L, Elewaut D, Van den Bosch F, Carron P, et al. Performance of an MRI scoring system for inflammation of joints and entheses in peripheral SpA: post-hoc analysis of the CRESPA trial. Rheumatology (Oxford). 2023; 62: 2130-8.

[29] Gassara Z, Feki A, Hakim Z, Ben Djmeaa S, Abid C, Kallel MH, et al. Foot involvement in psoriatic arthritis: Prevalence, clinical and radiological features. Foot Ankle Surg. 2024; 30: 465-70.

[30] Baraliakos X, Kiltz U, Appel H, Dybowski F, Igelmann M, Kalthoff L, et al. Chronic but not inflammatory changes at the Achilles’ tendon differentiate patients with peripheral spondyloarthritis from other diagnoses-Results from a prospective clinical trial. RMD Open. 2017; 3: e000541.

[31] Buehring B, Al-Azem N, Kiltz U, Fruth M, Andreica I, Kiefer D, et al. High Prevalence of Foot Insufficiency Fractures in Patients With Inflammatory Rheumatic Musculoskeletal Diseases. J Rheumatol. 2023; 50: 1071-7.

[32] Lems WF, Raterman HG, Geusens PPM. High Frequency of Foot Insufficiency Fractures in Patients With Rheumatic Diseases Referred for Magnetic Resonance Imaging: What Is the Clinical Relevance? J Rheumatol. 2023; 50: 971-3.

[33] Geusens P, van den Bergh J, Roux C, Chapurlat R, Center J, Bliuc D, et al. The Fracture Phenotypes in Women and Men of 50 Years and Older with a Recent Clinical Fracture. Curr Osteoporos Rep. 2024; 22: 611-20.

[34] Geusens P, Eisman JA, Singer A, van den Bergh J. Fracture liaison service. In: Bilezikian JP, Bouillon R, Clemens T, Compston J, Bauer DC, Ebeling PR, editors. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 9th ed. NJ: Wiley-Blackwell; 2019: 405-11.

[35] Lems WF, Dreinhöfer KE, Bischoff-Ferrari H, Blauth M, Czerwinski E, da Silva J, et al. EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures. Ann Rheum Dis. 2017; 76: 802-10.

[36] Hoong CWS, Saul D, Khosla S, Sfeir JG. Advances in the management of osteoporosis. BMJ. 2025; 390: e081250.

[37] Fink HA, MacDonald R, Forte ML, Rosebush CE, Ensrud KE, Schousboe JT, et al. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. Ann Intern Med. 2019; 171: 37-50.

[38] Ruffer N, Krusche M, Beil FT, Amling M, Kötter I, Rolvien T. Clinical features of methotrexate osteopathy in rheumatic musculoskeletal disease: A systematic review. Semin Arthritis Rheum. 2022; 52: 151952.

[39] Ragab AH, Frech RS, Vietti TJ. Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. Cancer. 1970; 25: 580-5.

[40] Ansell G, Evans S, Jackson CT, Lewis-Jones S. Cytotoxic drugs for non-neoplastic disease. Br Med J (Clin Res Ed). 1983; 287: 762.

[41] Preston SJ, Diamond T, Scott A, Laurent MR. Methotrexate osteopathy in rheumatic disease. Ann Rheum Dis. 1993; 52: 582-5.

[42] Maenaut K, Westhovens R, Dequeker J. Methotrexate osteopathy, does it exist? J Rheumatol. 1996; 23: 2156-9.

[43] Rolvien T, Creutzfeldt AM, Lohse AW, Amling M. Stress fractures in systemic lupus erythematosus after long-term MTX use successfully treated by MTX discontinuation and individualized bone-specific therapy. Lupus. 2019; 28: 790-3.

[44] Kanagawa H, Masuyama R, Morita M, Sato Y, Niki Y, Kobayashi T, et al. Methotrexate inhibits osteoclastogenesis by decreasing RANKL-induced calcium influx into osteoclast progenitors. J Bone Miner Metab. 2016; 34: 526-31.

[45] Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol. 1997; 24: 1489-94.

[46] Carbone LD, Kaeley G, McKown KM, Cremer M, Palmieri G, Kaplan S. Effects of Long-Term Administration of Methotrexate on Bone Mineral Density in Rheumatoid Arthritis. Calcif Tissue Int. 1999; 64: 100-1.

[47] Cranney AB, McKendry RJ, Wells GA, Ooi DS, Kanigsberg ND, Kraag GR, et al. The effect of low dose methotrexate on bone density. J Rheumatol. 2001; 28: 2395-9.

[48] di Munno O, Mazzantini M, Sinigaglia L, Bianchi G, Minisola G, Muratore M, et al. Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol. 2004; 31: 1305-9.

[49] Vestergaard P, Rejnmark L, Mosekilde L. Methotrexate, Azathioprine, Cyclosporine, and Risk of Fracture. Calcif Tissue Int. 2006; 79: 69-75.

[50] Robin F, Cadiou S, Albert J, Bart G, Coiffier G, Guggenbuhl P. Methotrexate osteopathy: five cases and systematic literature review. Osteoporos Int. 2021; 32: 225-32.

[51] Rolvien T, Jandl NM, Stürznickel J, Beil FT, Kötter I, Oheim R, et al. Clinical and Radiological Characterization of Patients with Immobilizing and Progressive Stress Fractures in Methotrexate Osteopathy. Calcif Tissue Int. 2021; 108: 219-30.

[52] von Brackel FN, Grambeck J, Barvencik F, Amling M, Oheim R. MTX Osteopathy Versus Osteoporosis Including Response to Treatment Data-A Retrospective Single Center Study Including 172 Patients. Calcif Tissue Int. 2024; 115: 599-610.

[53] Hauser B, Merriman A, Foley J, Golla J, McRorie E, Ralston SH. Methotrexate continuation increases fracture risk in patients who sustained lower limb insufficiency fractures. Ann Rheum Dis. 2025; 84: 554-61.

[54] Ozen G, Pedro S, Wolfe F, Michaud K. Medications associated with fracture risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2019; 78: 1041-7.

[55] Robin F, Ghossan R, Mehsen-Cetre N, Triquet L, Larid G, Coiffier G, et al. METHOFRACT, a methotrexate osteopathy multicentre cohort study. RMD Open. 2025; 11: e005941.

[56] Khan AA, Slart RHJA, Ali DS, Bock O, Carey JJ, Camacho P, et al.; International Working Group on DXA Best Practices. Osteoporotic Fractures: Diagnosis, Evaluation, and Significance From the International Working Group on DXA Best Practices. Mayo Clin Proc. 2024; 99: 1127-41.

[57] Buehring B, Thomas J, Wittkämper T, Baraliakos X, Braun J. Evaluation of the trabecular bone score (TBS) in routine clinical care of patients with inflammatory rheumatic and non-inflammatory diseases: Correlation with conventional bone mineral density measurement and prevalence of vertebral fractures. Z Rheumatol. 2020; 79: 1067-74. German.

[58] Yu W, Guan WM, Hayashi D, Lin Q, Du MM, Xia WB, et al. Vertebral fracture severity assessment on anteroposterior radiographs with a new semi-quantitative technique. Osteoporos Int. 2024; 35: 831-9.

[59] Buttgereit F, Palmowski A, Bond M, Adami G, Dejaco C. Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases. Nat Rev Rheumatol. 2024; 20: 417-31.

[60] Jin H, Jin H, Suk KS, Lee BH, Park SY, Kim HS, et al. Impact of anti-osteoporosis medication on refracture prevention following osteoporotic vertebral fracture: a systematic review and meta-analysis. Osteoporos Int. 2025;[Epub ahead of print].